Home › Merck, Foundation Medicine to Develop Companion Diagnostics for Immunotherapy

Merck, Foundation Medicine to Develop Companion Diagnostics for Immunotherapy

May 24, 2018

NEW YORK (GenomeWeb) – Foundation Medicine has inked a collaboration with Merck to develop companion diagnostic tests for use with Merck's anti-PD-1 immunotherapy drug Keytruda (pembrolizumab).

Under the agreement announced today, the companies plan to develop a pan-cancer CDx to measure microsatellite instability (MSI), CDx tests for tumor mutational burden (TMB), and other novel biomarkers of response.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Oct
02
Featured Webinar

Utilization of Multiple Molecular Testing Methodologies to Aid in Lung Cancer Patient Management

In the last few years several molecular testing methodologies — such as immunohistochemistry, PCR, and sequencing — have been approved by the US Food and Drug Administration to aid in the management of patients with lung cancer.  

Oct
04
Featured Webinar

Software Tools for NGS-Based Diagnosis of CFTR-Related Diseases in Routine Practice

This webinar will discuss the use of new software tools to support the diagnosis of CTFR-related disorders using next-generation sequencing.

Oct
10
Featured Webinar

Personalization of Oncology Pathways: Clinical Quality Initiatives Amid a Complex Molecular Landscape

This webinar will provide a first-hand look at how the Dana-Farber Cancer Center is adapting its oncology care strategy in light of the rapidly evolving molecular landscape.

Nov
05
Featured Webinar

Overcoming Challenges in Solid Tumor Testing with Advanced AI

Sponsored by
Sophia Genetics

With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.

What's Popular?

In Cancer

  1. Noridian Issues Draft LCD for GenomeDx Prostate Biopsy Genomic Classifier

  2. Canon Medical Systems Acquires Majority Stake in Cancer Genomic Profiling JV

  3. Predicine, Flagship Biosciences to Provide Combined Service

  4. Cancer Genetics, NovellusDx Sign Merger Agreement

  5. Resolution Bioscience Earns NY State Approval for Lung Cancer Liquid Biopsy Test

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2018 GenomeWeb LLC.  All Rights Reserved.